Why the world’s most discerning patients choose China.
For advanced cancer, complex cardiac disease, refractory neurosurgery, and rare conditions where outcomes depend on depth of expertise — China’s leading centers warrant serious evaluation.
39%
Of new global oncology trial starts originated in China in 2024 — up from ~5% a decade earlier.
7+
NMPA-approved CAR-T cell therapy products (2021–2025) — second only to the United States.
Why China now warrants serious evaluation.
A decade of national investment has shifted what the leading hospitals can do — visible in trial starts, drug innovation, and surgical case-mix complexity.
In 2024, China originated 39% of new global oncology trial starts and contributed to roughly 30% of all novel innovative drugs worldwide — from ~5% and ~1% respectively a decade earlier. At West China Hospital alone, ~187,000 surgical procedures were performed in 2023; a substantial proportion are classified Grade-IV under China’s official surgical complexity designation for the most complex cases.
China’s clinical leadership is not new. In 1963, Shanghai’s Chen Zhongwei performed the world’s first successful hand replantation — the operation that defined modern microsurgery; high-intensity focused ultrasound (HIFU) ablation was invented in China in the 1980s. What is new since 2015 is the breadth and scale.
Cardiac surgery volume
Flagship centers, 2023 · annual procedures
World-leading single-center volumes
75,000+
Single-port VATS at Shanghai Pulmonary — the most of any hospital worldwide
7,000+
Complex neurosurgeries a year at Beijing Tiantan — world's largest program
5,000+
Proton + carbon-ion patients at SPHIC — world's largest single-center program
47,443
Moyamoya patients in a nationwide cohort — among the largest documented globally
World's largest
Pediatric liver transplant program (Renji Hospital, Shanghai)
Sources: CDE 2024 Annual Report · IQVIA Innovation in China 2024 · West China Hospital Outline 2024 · 2024 Annual Report on Cardiovascular Health & Diseases in China · Cleveland Clinic Department of Cardiovascular Surgery 2023 · National Heart Centre Singapore 2023 · Bumrungrad Hospital 2023 · Shanghai Pulmonary Hospital · Shanghai Proton & Heavy Ion Center · Miao et al., EClinicalMedicine 2021 (moyamoya) · Renji Hospital.
“Concentrated volume measurably narrows variance in surgical and post-operative outcomes.”
0.4%
Fuwai · 30-day mortality (15-year sustained)
Fuwai Hospital Cardiovascular Surgery Outcomes Report · 2023
China-developed standards, now adopted internationally.
A measurable shift: China is no longer only adopting global standards — it is beginning to set them. The Beijing Protocol for haploidentical (half-matched) stem-cell transplantation, developed by Prof. Huang Xiaojun at Peking University, is now an international reference for transplantation without a perfectly matched donor. Pulmonary artery denervation (PADN), validated by Prof. Chen Shaoliang in Nanjing, has been incorporated into international pulmonary-hypertension guidelines as an adjunctive option — among the first Chinese cardiology techniques to enter international consensus. Subxiphoid uniportal VATS, pioneered at Shanghai Pulmonary Hospital in 2014, is now performed at major thoracic centers worldwide.
Sources: Huang XJ et al., haploidentical HSCT (Beijing Protocol) · Zhang H et al., PADN-CFDA randomized trial, JACC Cardiovasc Interv 2022 · Shanghai Pulmonary Hospital (subxiphoid uniportal VATS, 2014).
Depth at partner hospitals.
National referral centers anchor distinct limbs of complex disease care — each with published, peer-reviewed evidence of its own performance.
Cardiac · Cardiovascular
Fuwai Hospital
18,874
Cardiovascular surgeries (2023) — world's largest single-center volume. 30-day mortality 0.4%; cardiovascular surgical mortality kept below 1% for 15 consecutive years.
Oncology · GI & Thoracic
Peking U. Cancer Hospital
210K+
Gastric cancer biobank samples with 20+ year follow-up. Led first phase-III RCT of laparoscopic D2 gastrectomy (JAMA, 2019).
Neurosurgery · Complex brain & skull-base
Beijing Tiantan Hospital
7,000+
Complex neurosurgeries annually — world's largest single-center program. Home to the Beijing Neurosurgical Institute (founded 1960, relocated to Tiantan 1982). National Clinical Research Center for Neurological Diseases.
The three institutions above anchor cardiac, oncology, and neurosurgery in the partner network — chosen to illustrate the depth-by-specialty pattern. The full network extends across oncology, hematology, transplant, structural heart, pediatric subspecialties, and rare-disease referral programs at internationally-accredited private hospitals and Grade 3A academic centers.
See the full network →Sources: 2024 Annual Report on Cardiovascular Health & Diseases in China · JAMA 2019 (laparoscopic D2 gastrectomy phase III RCT) · China International Neuroscience Institute.
Therapies available in China.
Five categories where China’s clinical menu is routinely deeper, broader, or available earlier than what international patients can typically reach in their country of residence.
Category 01
Cellular & immune therapies
Includes equecabtagene autoleucel (Fucaso®), the world's first fully-human BCMA-targeted CAR-T; satri-cel (claudin18.2), China's first solid-tumor CAR-T (NDA review May 2025); and pCAR-19B, the first humanized pediatric CAR-T. 300+ active CAR-T trials run concurrently — the largest cellular-therapy clinical pipeline globally.
For: Relapsed or refractory hematologic cancers — lymphoma, leukemia, multiple myeloma; pediatric ALL; and solid tumors with cellular-therapy-amenable targets.
Category 02
Tumor-agnostic targeted therapies
Includes larotrectinib (NTRK fusion), selpercatinib (RET-altered), and sotorasib (KRAS-G12C-mutated). Therapy matched to mutation, not cancer site.
For: Solid tumors carrying actionable genomic alterations — across many cancer types.
Category 03
China-originated next-generation biologics
Includes ivonescimab, the first PD-1/VEGF bispecific to outperform pembrolizumab head-to-head in PD-L1+ NSCLC (Lancet, 2025) — a globally-first result from a Chinese-developed drug.
For: Advanced cancer patients seeking next-generation regimens at the global frontier.
Category 04
Globally-approved therapies via special access
FDA-, EMA-, and PMDA-approved therapies not yet registered on the Chinese mainland — including SMA, hereditary angioedema, and rare-cancer agents. Import authorization in 3–7 days.
For: Rare diseases, pediatric conditions, or refractory cases where the indicated therapy is approved internationally but not in the patient's country of residence.
Category 05
China-developed medical devices & platforms
Cardiology, neurosurgery, oncology, and orthopedic platforms now developed in China — the uEXPLORER total-body PET-CT, the Sinovation neurosurgical robot (NMPA + FDA), TiRobot, the SHURUI single-port robot, and HIFU — increasingly reach the same regulatory bar as US/EU devices, sometimes earlier and at lower cost.
For: Patients seeking advanced procedures that use globally-validated Chinese medical technology not yet adopted at scale elsewhere.
Mechanism 01 · Domestic approval
NMPA approval pathway
Categories 01–03 are accessed through China's national regulator. Domestic frontier-therapy is no longer a follower indication — in many areas, NMPA approvals are now contemporaneous with or ahead of FDA/EMA.
Mechanism 02 · Special-access zone
Hainan Boao Lecheng
Category 04 is accessed through a State Council-authorized special-access pathway operating in Hainan Province since 2013 — nine designated hospitals, 200,000+ patient visits cumulatively (domestic and international combined). Patient-level import authorization in 3–7 days.
Sources: Huang et al., Clinical Pharmacology & Therapeutics 2025 · Lancet 2025 (ivonescimab) · China Food & Drug News, Nov 2025 · Hainan Provincial Government.
Therapy availability is matched to diagnosis case-by-case →
“Therapy matched to mutation, accessed through domestic approval or State Council special access.”
~520
International drugs & devices via Boao Lecheng · 2025
China Food & Drug News · November 2025
Cost and pricing structure.
China prices treatment against a domestic cost base — not against US list prices. Four structural drivers explain the difference; none are shortcuts on standards.
01
Manufacturing
In-country drug production eliminates import and distributor margins.
02
Procurement
National volume-based procurement reference-prices high-volume drugs.
03
Throughput
Higher facility throughput amortizes fixed costs across far more cases per year.
04
Compensation
Physician compensation is indexed to local cost of living.
| Treatment | US | Singapore | China | Savings vs US |
|---|---|---|---|---|
CAR-T Cell Therapy CD19+ or BCMA+ hematologic | $373–530K | $300–400K | $70–200K | Up to 85% |
Cardiac Bypass (CABG) Multi-vessel, inpatient | $78–123K | $40–80K | $30–50K | Up to 75% |
Knee Replacement Unilateral, all-in | $29–50K | $19–30K | $8–14K | Up to 75% |
Proton Therapy Full course | $150–200K | $30–90K | $45–55K | Up to 70% |
Lecanemab (Alzheimer's) Annual therapy | $26,500/yr | — | ~$8,970/yr | ~66% |
Nusinersen (SMA) Per dose | ~$125,000 | — | ~$5,180 | ~96% |
US benchmarks: CAR-T — FDA list prices, PMC12796026; CABG — Statista 2019 median & PMC9742101; knee — KFF 2024; proton — Wiley/JMRS 2024. China: Shanghai Proton & Heavy Ion Center; Tandfonline 2023.
Regulatory standards, in parallel.
Two regulatory tracks govern partner institutions — private hospitals accredited internationally, and public Grade 3A academic centers under NHC and NMPA oversight. Both align with ICH-GCP.
Private track United Family Healthcare and peers | Public track Grade 3A academic medical centers | |
|---|---|---|
| Accreditation | JCI — since 2005, China's first. CAP pathology. ~45 JCI organizations nationally. | Grade 3A — 1,795 hospitals, less than 5% of all hospitals (NHC, 2023). |
| Ethics & Consent | JCI-validated IRB; Western-standard informed consent; full English documentation. | Ethics committees aligned with ICH-GCP E6(R2); NMPA oversight. |
| Infection Control | JCI-validated; dedicated international-patient ICUs with single-room isolation. | National standards; dedicated international wards at flagship centers. |
| Trial Standards | GCP Phase I–IV; sponsor-investigator and industry trials. | GCP mandatory; National Clinical Research Centers as primary sites for first-in-human trials. |
China’s National Clinical Research Centers coordinate first-in-human trials and rare-disease referral nationally — among them the National Clinical Research Center for Neurological Diseases (Beijing Tiantan), the National Center for Cardiovascular Diseases (Fuwai), and the National Cancer Center (Cancer Hospital, CAMS). Several flagship centers also publish bilingual annual outcomes reports comparable to those of leading Western academic medical centers — Fuwai’s Cardiovascular Surgery Outcomes Report among them.
Sources: Fortune Journals — JCI in Chinese Hospitals · NHC Statistical Bulletin 2023.
A recent patient case.
Specific diagnosis. Specific treatment. Specific timeline. One recent case from the partner network — anonymized at the family’s request.
Relapsed multiple myeloma — CAR-T not approved in patient’s country of residence.
M., 45 · India · Treated at Beijing United Family Hospital · February 2026
Why this case was routed to China
- Time-to-treatment within 14 days from case submission to confirmed admission.
- Access to equecabtagene autoleucel (Fucaso®) the world's first fully-human BCMA CAR-T.
- Pre-arrival multi-disciplinary team review began three weeks before admission.
Dec '25
Decision
Dec '25
Arrival
Jan '26
Cell collection
Feb '26
Infusion
Now
Surveillance
Outcome
Tolerated infusion with standard CAR-T side-effect management. Discharged in stable condition. Post-treatment surveillance ongoing in coordination with the patient’s primary hematologist.
“It wasn’t a choice between geographies — it was about adding capability to the team.”
— Family member, on behalf of patient M.
Shared with informed consent for educational purposes. Identifying details modified. Individual outcomes are not predictive of results for other patients with similar diagnoses.
Further patient cases →
“A treatment that exists in China, accessed through a clinical case-management layer.”
<14d
Median case submission to treatment start
MediPath Fast-Track Protocol · eligible cases
Compared with other destinations.
Thailand, Singapore, and China each specialize. Matching diagnosis to destination is the most consequential decision a medical-travel patient makes.
| Need | Thailand | Singapore | China |
|---|---|---|---|
Advanced / metastatic cancer Stage III–IV oncology, multi-modality regimens | ★ | ★★ | ★★★Leads |
Cellular & immune therapies CAR-T, NK, gene-modified cell therapies | — | ★ | ★★★Leads |
Complex cardiac & structural heart CABG, valve replacement, TAVI | ★ | ★★ | ★★★Leads |
Refractory neurosurgery Complex cerebrovascular, skull base, DBS | — | ★ | ★★★Leads |
Access to frontier therapies Trial-stage agents, tumor-agnostic targets | ★ | ★★ | ★★★Leads |
English-language continuity Native-English clinical and concierge | ★★ | ★★★Leads | ★★ |
Elective & wellness Cosmetic, dental, fertility, executive health | ★★★Leads | ★★ | ★ |
Cost efficiency Versus US list pricing | ~65% lower | ~45% lower | 60–80% lowerLeads |
For complex, advanced, or refractory disease — and frontier therapy access — China leads. For elective and English-default care, other destinations may serve a patient better.
All of this exists. Reaching it on your own does not.
Seven sections set the case. Translating it into a real treatment — across language, jurisdiction, referral protocols, cultural needs, and post-treatment continuity — is the work the next section answers.
How MediPath works.
We exist for the work between deciding on China and being treated in China — case review, hospital and physician selection, regulatory pathway management, language, logistics, cultural needs, and continuity of care with the patient’s primary physician. One clinical case manager throughout.
01
Case submission
Secure upload of records and imaging. Initial clinical review within 48 hours.
02
Remote MDT
Multi-disciplinary consultation with partner specialists. Treatment plan and itemized quote delivered.
03
Travel & arrival
Visa, flights, VIP airport reception, private transport, accommodation for patient and family.
04
Treatment
On-the-ground case manager, real-time translation, daily updates, 24/7 concierge line.
05
Continuity of care
Discharge documentation in English/Arabic. Handover to the patient's primary physician. Scheduled remote follow-up.
<14 days
From case submission to confirmed treatment start at a partner hospital — Fast-Track Protocol, eligible cases.
Context: median US cancer diagnosis-to-treatment interval is 29 days (Khorana et al., PLOS One 2019). Fast-Track Protocol is a brand service commitment, not an industry benchmark.
— Across the journey
International patient services, integrated by design.
Language
English across all international-patient programs. Arabic and Russian coordinators at flagship centers. Real-time medical translation during all consultations.
Visa & logistics
Medical visa facilitation, invitation letters, flight booking, VIP airport reception, private transport, hotel and serviced-apartment accommodation for patient and family.
Cultural & dietary
Halal dining available at all partner hospitals. Prayer facilities, qibla direction in rooms on request. Gender-sensitive care, female physicians available. Ramadan-aware scheduling.
Family & continuity
Family accommodation integrated — patient suites designed for relatives. 24/7 concierge for medical, logistical, or personal needs. Daily progress updates to designated family contacts.
MediPath is the clinical access layer between international patients and China’s complex medical system.
If your diagnosis is complex, your options should not be.
Submit your case for confidential review. 48-hour clinical response, no obligation.